403. Can BioTech Extend Life to 150 Years? Gene Editing, and Investing in the Future of Life Sciences (Risa Stack)

Investor Stories 396: Visionary Founders (Chau, Whitmire, Garcia)

477. The Biggest Misconceptions About AI Agents, Why Defensibility Doesn’t Matter at Seed, and Whether the AI Center of Gravity Is Shifting to China (Aaref Hilaly)

Investor Stories 395: Best LP Question (Upham, Ho, Yunger)

476. Fixing Education with a Startup Mentality: The Innovative Micro Schools-Model Backed by Founders Fund, Khosla, and Sam Altman (Ryan Delk)

Investor Stories 394: Lessons Learned (Chase, Boduch, Whitmire)

475. Non-Dilutive Capital That’s More Flexible Than Debt, Why Ruthless Prioritization Leads to Scale, and the One Ingredient That Makes a Company Investable at Any Stage (Vince Hsieh)

Investor Stories 393: Why I Passed (Ho, Yunger, Chau)

474. The VC Myth, AI Hype, Mastering GTM, and The Smart Approach to Capital Strategy and Achieving Startup Success (Kyle York)

DNA als Plattform der Zukunft

Trevor Martin (Mammoth Biosciences) and Ursheet Parikh (Mayfield) - Building Biotech to Last

Curing disease with CRISPR with Trevor Martin from Mammoth Biosciences

Startup Insider Daily • Recap • Fynn Kliemann • CRISPR • Turing-Test • Onecoin • Google Maps • Tesla • Apple • Ororatech

CRISPR/Cas9 mit Myopax

Startup Insider Daily • Tesla-Hack • Insolvenzantragspflicht • Ripple • Basecamp-Exodus • CRISPR • Netflix

E42: China's tech crackdown, CRISPR breakthrough, practical climate change solutions & more

Trailblazing discoveries in Gene Editing Solutions